Published in:

01-05-2004

Cross-Resistance Studies of Isogenic Drug-Resistant Breast Tumor Cell Lines Support Recent Clinical Evidence Suggesting that Sensitivity to Paclitaxel may be Strongly Compromised by Prior Doxorubicin Exposure

Authors: Baoqing Guo, David J. Villeneuve, Stacey L. Hembruff, Angie F. Kirwan, David E. Blais, Michel Bonin, Amadeo M. Parissenti

Published in: Breast Cancer Research and Treatment | Issue 1/2004